NCT02698280

Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.

Detailed description

Although anti-angiogenesis therapy for glioblastoma(GBM) are showing promise, GBMs often develop resistance to treatment within months or weeks after salvage therapy. There are still no effective markers to predict the response rate to bevacizumab. So the investigators initiate a single-arm Phase II study to evaluate the efficacy and tolerability of bevacizumab and nimustine regimen and to explore the predictive markers in patients with recurrent high-grade glioma.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
DRUG	Nimustine	Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.

Timeline

• Start date: 2015-07-01
• Primary completion: 2018-01-01
• Completion: 2018-05-01
• First posted: 2016-03-03
• Last updated: 2018-07-31

Locations

1 site across 1 country: China